Global scleroderma therapeutics market to reach $3.52 billion by 2034

7 articles · Updated · Fortune Business Insights · May 8

The market was valued at $1.83 billion in 2025 and is forecast to rise from $1.98 billion in 2026, with North America leading at $0.74 billion in 2025.
Growth is driven by earlier diagnosis, demand for treatments targeting fibrosis, inflammation and organ damage, and expanding research into biologics, cell therapies and label extensions.
Immunosuppressants currently dominate treatment, while IL-6 inhibitors are expected to grow fastest; limited disease-modifying options and difficult trial design remain major constraints.

With a projected $3.5B market, can drug makers overcome the trial failures that have historically plagued scleroderma research?

Can emerging AI diagnostic tools finally eliminate the critical and lengthy delays in identifying scleroderma patients?

Beyond just slowing scleroderma, can new therapies actually reverse the devastating organ damage it causes?